HHC
LFCR icon

Hutchin Hill Capital’s Lifecore Biomedical LFCR Stock Holding History

Hutchin Hill Capital’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,300
Closed -$153K – 857
2017
Q2 		$153K Buy
+10,300
New +$143K 0.01% 804

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hutchin Hill Capital's LFCR Position: Q3 2017 in Review

Hutchin Hill Capital sold out of Lifecore Biomedical (LFCR) in Q3 2017, closing a stake of 10,300 shares — an estimated $153K sold.

Hutchin Hill Capital first reported a position in LFCR in Q2 2017 and held it in 1 quarter. The position peaked at $153K in Q2 2017. 95 funds tracked by Wall St. Rank hold LFCR as of Q3 2017.

  • Hutchin Hill Capital reported no remaining Lifecore Biomedical position as of Q3 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 10,300 Lifecore Biomedical shares in Q3 2017, an estimated $153K.
  • Hutchin Hill Capital first reported a position in Lifecore Biomedical in Q2 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Lifecore Biomedical position peaked at $153K in Q2 2017.
  • 95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.